* to investigate the prevalence and time course of autonomic dysfunction in acute ischemic stroke patients;
* to evaluate the influence of lesion location on autonomic dysfunction;
* to identify patterns of structural and functional brain connectivity within the central autonomic control circuits associated with autonomic dysfunction; and
* to explore causal models of the link between brain lesions; cardiac, immunological and endocrine biomarkers; and dysautonomia.
Researchers will compare patients with acute ischemic stroke to patients with transient ischemic attacks to study the effect of acute ischemic brain lesions.
Participants will
* undergo cardiovascular autonomic function testing;
* receive structural and functional MR imaging;
* provide blood samples for determinaton of serological biomarkers auf dysautonomia.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Diagnosis of either
* acute ischemic stroke with either an ischemic lesion visible on CT/MRI or persistent focal deficits 24 hours after symptom onset, or
* Transient ischemic attack with transient clinical deficits including motor or speech disturbance and not restricted to isolated vertigo/dizziness, visual disturbance, or sensory disturbance.
* symptom onset within 72h prior to hospital admission,
* a pre-stroke/TIA ability to walk without help from another person (modified Rankin scale score \< 4),
* age \> 18 years, and
* informed consent by either the patient or a legal representative (including a spouse)
Exclusion Criteria:
* In-hospital stroke,
* contraindications to MR imaging (e.g., claustrophobia, pregnancy, pacemakers, implants),
* known moderate to severe dementia,
* previous structural brain damage (except leukoariosis due to cerebral small vessel disease),
* hemodynamically relevant stenosis of the common or internal carotid artery, or
* left heart failure with estimated left ventricular ejection fraction \< 50%,
* concomitant systemic illness that can lead to dysautonomia, such as an active infection, thyroid disease, or neurodegenerative disorder (e.g. PD, MSA).
Primary outcome measure(s)
Autonomic dysfunction — 3-5 days after stroke onset Cardiovagal and Adrenergic Scores on the Composite Autonomic Scoring Scale (0-7, higher values indicate greater dysfunction)
Trial sites (1)
Facility
City
Region
Status
University Medical Center Hamburg-Eppendorf
Hamburg
Free and Hanseatic City of Hamburg
Recruiting
More Universitätsklinikum Hamburg-Eppendorf trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.